SOA Wealth Advisors LLC. Sells 1,121 Shares of Pfizer Inc. (NYSE:PFE)

SOA Wealth Advisors LLC. lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 12.0% during the 1st quarter, Holdings Channel reports. The fund owned 8,216 shares of the biopharmaceutical company’s stock after selling 1,121 shares during the period. SOA Wealth Advisors LLC.’s holdings in Pfizer were worth $208,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Kennebec Savings Bank boosted its position in Pfizer by 25.9% during the 1st quarter. Kennebec Savings Bank now owns 2,396 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 493 shares in the last quarter. Wynn Capital LLC lifted its holdings in shares of Pfizer by 64.5% during the 1st quarter. Wynn Capital LLC now owns 36,279 shares of the biopharmaceutical company’s stock valued at $919,000 after purchasing an additional 14,220 shares during the last quarter. KMG Fiduciary Partners LLC lifted its holdings in shares of Pfizer by 9.8% during the 1st quarter. KMG Fiduciary Partners LLC now owns 116,161 shares of the biopharmaceutical company’s stock valued at $2,944,000 after purchasing an additional 10,352 shares during the last quarter. Griffith & Werner Inc. lifted its holdings in shares of Pfizer by 13.3% during the 1st quarter. Griffith & Werner Inc. now owns 116,596 shares of the biopharmaceutical company’s stock valued at $2,955,000 after purchasing an additional 13,679 shares during the last quarter. Finally, Miracle Mile Advisors LLC lifted its holdings in shares of Pfizer by 6.2% during the 1st quarter. Miracle Mile Advisors LLC now owns 233,234 shares of the biopharmaceutical company’s stock valued at $5,910,000 after purchasing an additional 13,534 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on PFE. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective for the company. Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Stock Performance

NYSE PFE opened at $23.36 on Monday. The stock has a 50-day simple moving average of $22.95 and a two-hundred day simple moving average of $25.00. The firm has a market capitalization of $132.81 billion, a P/E ratio of 16.57, a PEG ratio of 0.64 and a beta of 0.57. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s revenue was down 7.8% on a year-over-year basis. During the same quarter last year, the business posted $0.82 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.36%. Pfizer’s payout ratio is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.